Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics Inc. (KPTI) has a significant shareholder group led by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reporting beneficial ownership of 1,297,297 shares of common stock. This position represents 5.7% of Karyopharm’s outstanding common stock.
For each reporting person, there is no sole voting or dispositive power and 1,297,297 shares of shared voting and shared dispositive power. The securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander, and the reporting persons state this should not be construed as an admission of beneficial ownership of those securities.
Karyopharm Therapeutics Inc. (KPTI) disclosed that Chief Accounting Officer Kristin Abate sold 19 shares of common stock on September 1, 2026 at $2.02 per share. According to the disclosure, this broker-assisted sale was made under a durable automatic sale instruction plan to satisfy withholding tax liability from vesting restricted stock units and is described as non-discretionary. After the sale, Abate directly held 23,782 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. (KPTI) reported that it has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis. The company has also requested Priority Review, which, if granted, could shorten the FDA review to about six months.
The submission draws in part on Phase 3 SENTRY trial data, including what the company describes as a promising signal of overall survival and use of spleen volume reduction ≥35% (SVR35) as a surrogate endpoint. Karyopharm plans to use long-term overall survival data from SENTRY to verify clinical benefit for potential conversion from accelerated to traditional approval. The company also reiterates significant risks, including that substantial doubt exists regarding its ability to continue as a going concern.
RA Capital Management, L.P. and affiliated reporting persons report beneficial ownership of 2,302,504 shares of Karyopharm Therapeutics Inc. common stock as of June 30, 2026, representing 9.99% of the class. The position is held through RA Capital Healthcare Fund, L.P., with all voting and dispositive power shared among the reporting persons.
The Fund directly holds 1,917,354 shares of common stock plus pre-funded and common warrants. Warrant exercises are limited by Beneficial Ownership Blockers that prevent ownership above 9.99% of outstanding common stock.
Karyopharm Therapeutics Inc. is the subject of an amended Schedule 13G filing in which Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz (each a “Filer”) report that they beneficially own 0.00 shares of Karyopharm common stock, representing 0.0% of the class. The filing states that each Filer has no sole or shared voting power and no sole or shared dispositive power over any Karyopharm common shares, indicating ownership of 5 percent or less of the class as of June 30, 2026.
Karyopharm Therapeutics reported total revenue of $68.5 million for the six months ended June 30, 2026, roughly flat versus 2025, with XPOVIO net product revenue rising to $59.9 million and license and other revenue declining to $8.6 million. Operating loss narrowed to $49.3 million, but a sharp increase in other expense led to a net loss of $89.4 million versus $60.7 million a year earlier.
Cash, cash equivalents and investments totaled $65.1 million, while total liabilities were $441.5 million, including a senior secured term loan of $125.4 million, New 2029 Notes of $98.7 million, 2028 Notes of $25.9 million, a $72.3 million deferred royalty obligation and warrant liabilities. Stockholders’ deficit widened to $(330.2) million. The company expects its current liquidity plus anticipated revenues to fund operations only into September 2026 and discloses substantial doubt about its ability to continue as a going concern.
A $15.8 million term-loan principal payment is due September 10, 2026, plus about $10.1 million of interest across its debt on September 30, 2026; management warns it may be unable to fund operations after these payments without new financing or strategic transactions and may need to consider bankruptcy. Clinically, the Phase 3 SENTRY trial in myelofibrosis met its spleen-volume endpoint but not symptom improvement, and Karyopharm plans an August 2026 sNDA seeking accelerated approval for selinexor plus ruxolitinib. A separate Phase 3 endometrial cancer study did not meet its primary endpoint, and the DLBCL indication for XPOVIO is being voluntarily withdrawn.
Karyopharm Therapeutics Inc. reported second quarter 2026 total revenue of $33.4 million, down from $37.9 million a year earlier, with U.S. XPOVIO net product revenue rising modestly to $30.8 million. License and other revenue fell sharply to $2.6 million as a Menarini R&D funding obligation expired.
R&D and SG&A expenses declined year over year, but the company still posted a net loss of $67.0 million, driven by an operating loss of $22.5 million and $44.5 million in non-operating expense, including $13.1 million of interest and $32.1 million of non-cash derivative and warrant-related expense. Cash, cash equivalents, restricted cash and investments totaled $65.4 million at June 30, 2026.
The company reaffirmed 2026 guidance for total revenue of $130–$150 million and U.S. XPOVIO revenue of $115–$130 million, and expects R&D plus SG&A of $230–$245 million. Management is actively evaluating financing opportunities and strategic alternatives as it faces a $15.8 million senior term-loan principal payment due September 10, 2026 and a $10.0 million minimum liquidity covenant that could be breached absent additional actions. Karyopharm remains on track to submit an August sNDA under the Accelerated Approval pathway for selinexor plus ruxolitinib in myelofibrosis, supported by positive Phase 3 SENTRY data, while its Phase 3 endometrial cancer trial did not meet its primary endpoint.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 1,536,736 shares of Karyopharm Therapeutics Inc. common stock, including 15,414 shares issuable upon exercise of warrants, held through Adage Capital Partners, L.P.
This position represents 6.78% of Karyopharm’s common stock, based on 22,662,943 shares outstanding as of May 7, 2026. All voting and dispositive authority over these shares is reported as shared, with no sole voting or dispositive power listed for any reporting person.
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of 1,429,197.87 shares of Karyopharm Therapeutics Inc. common stock on an amended Schedule 13G as of June 30, 2026. This position represents 6.3% of the outstanding common stock.
The filing states no sole voting or dispositive power and shared voting and dispositive power over all 1,429,197.87 shares. The securities are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser, which is a subsidiary of The Goldman Sachs Group, Inc. The Goldman Sachs reporting units disclaim beneficial ownership of certain client and fund-related holdings as described.
Karyopharm Therapeutics reported topline Phase 3 results from its XPORT-EC-042 trial of selinexor maintenance in TP53 wild-type advanced or recurrent endometrial cancer; the study did not meet its primary endpoint of progression free survival.
In the modified intent-to-treat population (n=236), median PFS was 12.75 months with selinexor versus 7.43 months with placebo (hazard ratio 0.76; one-sided p=0.0791), and safety was consistent with the established profile, with no new signals. Ongoing selinexor studies in other indications are unchanged.
Karyopharm plans an August 2026 supplemental New Drug Application seeking FDA accelerated approval of selinexor plus ruxolitinib in myelofibrosis, based on Phase 3 SENTRY data showing statistically significant SVR35 spleen responses at week 24, supportive survival and biomarker findings, and overall safety. The company is also exploring financing transactions and strategic alternatives with advisors, including Centerview Partners.